Organon & Co.

Organon & Co. is a global healthcare company headquartered in Jersey City, New Jersey, USA. Established in 2020 as a spin-off from Merck & Co., its core mission is to deliver impactful medicines and solutions for a healthier everyday, with a vision focused on improving the health of women throughout their lives.

The company's diverse portfolio is structured around three key areas: women's health, biosimilars, and established brands. In women's health, Organon offers products for reproductive medicine, contraception (e.g., Nexplanon), fertility (e.g., Follistim), maternal health, and conditions such as bacterial vaginosis, breast cancer, menopause, and osteoporosis. Its biosimilars segment provides more affordable treatment options for oncology and immunology (e.g., Hadlima, POHERDY, BILDYOS, TOFIDENCE). The established brands franchise includes therapies for a wide range of conditions, including cardiovascular disease (e.g., COZAAR), neurology, dermatology, autoimmune, and respiratory conditions (e.g., ASMANEX). Organon's products are available in over 140 countries globally.

Led by CEO Joseph Morrissey, Organon has been actively involved in strategic developments. In April 2026, Sun Pharmaceutical Industries Limited announced an agreement to acquire Organon & Co. for $11.75 billion, with the transaction anticipated to close in early 2027. Other recent activities include the European Commission's approval of POHERDY® (pertuzumab), a biosimilar, in April 2026, and the licensing of MIUDELLA®, a hormone-free intrauterine device, in June 2026.